Welcome to the Rader Lab

The Rader Lab has a history of leveraging human gene discovery to elucidate the biology and molecular physiology of genes and pathways that influence lipoprotein metabolism, cardiometabolic traits, and cardiovascular diseases. More recently, Dr. Rader’s extensive expertise in lipid metabolism has increasingly led to a focus on neurodegeneration, using human genetics as a starting point. State-of-the-art technologies including CRISPR gene targeting in human iPSC cells, single-cell RNA sequencing, and multi-omics are employed in the investigation of complex diseases. The Rader lab research team integrates computational genomics, fundamental mechanistic investigation in cell and animal model systems, and targeted deep phenotyping in human subjects to establish clinical relevance and accelerate translation of research insights to potential treatment of human cardiometabolic disorders.


Learn more about our research




  • Grant Funding: Recently announced funding for Dr. Rader’s research program, through the NIH NHLBI R35 Outstanding Investigator Award and the AHA Merit Award mechanisms, will provide the means to carry out an ambitious and synergistic plan to innovate, scale, systematize, and sustain efforts in bridging genomic ‘dry lab’ discovery, functional ‘wet lab’ experimentation, and human ‘deep phenotyping’ studies in order to better understand the molecular mechanisms linking lipid metabolism and a range of cardiovascular diseases.


  • The Philadelphia 76ers recognize Drs. Dan Rader and Kate Sullivan, who co-direct the Undiagnosed Disease Program at the University of Pennsylvania School of Medicine and Children’s Hospital of Pennsylvania. (Posted Feb. 27, 2024 on 76ers X feed). See photo here.